Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00233662 · ClinicalTrials.gov registry record · Phase 3
Safety and Tolerability of Repeat Courses of IM Alefacept
A Phase 3 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
NCT00233662 is a Phase 3 study that has completed, run by Biogen. The registered enrollment target is 400 participants.
The verdict
NCT00233662, a Phase 3 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether repeat courses of alefacept, administered intramuscularly, are safe when given to chronic plaque psoriasis patients who are receiving standard dermatology treatments.
Interventions
- DRUG Alefacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2002-12-01 |
| Est. Completion | 2005-12-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00233662
The ClinicalTrials.gov registry entry for NCT00233662 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alefacept is the first listed.
NCT00233662 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00233662 about?
NCT00233662 is a clinical study titled "Safety and Tolerability of Repeat Courses of IM Alefacept". The purpose of this study is to determine whether repeat courses of alefacept, administered intramuscularly, are safe when given to chronic plaque psoriasis patients who are receiving standard dermatology treatments.
What is the current status of trial NCT00233662?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2002-12-01. Estimated completion is 2005-12-01.
What interventions are being tested in trial NCT00233662?
The interventions under investigation include: Alefacept (DRUG).
Who is sponsoring clinical trial NCT00233662?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.